The $303 Billion CRDMO Opportunity: What's Really Giving India the Upper Hand

Every few years, a new acronym makes its way into pharma boardrooms and investor decks, and it usually takes a while before anyone takes it seriously. CRDMO happens to be the latest one making the rounds. But unlike most buzzwords that fizzle out once the excitement fades, this one actually has real numbers to back it up. The global Contract Research, Development, and Manufacturing Organization market is on track to hit roughly $303 billion by 2028, growing at a compound annual rate of nearly 9 percent. India holds a modest slice of that pie today. Where the country goes from here is the more interesting story.

In simple terms, a CRDMO is what you get when a Contract Research Organization and a Contract Development and Manufacturing Organization join forces into one integrated model. Rather than a pharma company having to go shopping separately for a discovery partner, a clinical trials partner, and a manufacturing partner, a CRDMO takes care of all three under one roof, carrying a molecule right from early-stage research through to commercial-scale production.

For global pharma majors constantly under pressure to cut costs and shorten drug development timelines, that's really the whole appeal. Outsourcing research and manufacturing frees up their capital and talent to focus on what they actually do best, discovering drugs and getting them to market, instead of running production facilities.

Why India, and Why Now?

India currently holds somewhere around 3 to 3.6 percent of the global CRDMO market, translating to a domestic industry worth roughly $3 to 3.5 billion. That sounds small next to China's share, which is nearly four times larger. But the growth rate tells a different story. India's CRDMO sector is expanding at close to 13 to 15 percent CAGR, comfortably ahead of the global average, and multiple industry estimates now put the sector on track to reach $22 to 25 billion by 2035.

A few structural factors explain why global pharma is increasingly looking India's way.

Cost leadership that hasn't eroded. India continues to offer meaningfully lower operating costs than Western manufacturing hubs, without the steep quality trade-off that used to accompany cheaper sourcing.

Speed to project start. Indian CRDMOs are reportedly getting new projects operational up to 90 percent faster than comparable Western facilities, a difference that matters enormously when a drug's patent clock is already running.

A China-plus-one pivot that's no longer theoretical. Global supply chain realignment away from over-reliance on China has moved from boardroom slide to actual capital allocation, and India is one of the clearest beneficiaries. Industry estimates place the value up for grabs from this shift alone at $10 to 15 billion.

Government capital behind the ambition. Over ₹25,000 crore in government funding has been directed toward building a more self-sufficient, innovation-led pharma and biotech ecosystem, a meaningful signal that this isn't purely a private sector bet.

A widening technology base. India's traditional strength has been small molecule chemistry. That's now expanding into newer modalities like antibody drug conjugates and DNA- and RNA-based therapeutics, categories growing at 25 to 35 percent annually worldwide. This shift matters because it's where India moves from being a low-cost execution partner to an actual innovation partner.

CRDMO growth doesn't exist in isolation. It sits inside a larger and arguably more important shift in how India manufacturing investment themes are being framed by both global capital and domestic investors. The same forces pulling pharma contract manufacturing toward India cost competitiveness, policy support, and supply chain diversification are visible across electronics, specialty chemicals, and precision engineering as well.

What makes pharma CRDMO's investment in India particularly compelling within that broader theme is the combination of high entry barriers and long client relationships. Once a global pharma company qualifies an Indian CRDMO partner for a molecule, switching costs are steep. Regulatory approvals, quality audits, and manufacturing validations don't get repeated lightly. That stickiness is exactly what makes the sector attractive to long-horizon capital rather than short-term traders.

Public market investors have had listed CRDMO names on their radar for a while. What's shifted more recently is the level of venture capital in pharma India directed at earlier-stage and mid-sized players in the space, companies still scaling their capacity, expanding into new modalities, or building out specialized facilities that larger incumbents haven't gotten to yet.

This is also where SME investment opportunities in India intersect meaningfully with the pharma manufacturing story. A number of the companies positioned to benefit from the China-plus-one shift and the ADC and biologics wave aren't the household pharma names. They're smaller, specialized manufacturers building capacity in categories where demand is outpacing existing supply, exactly the profile that tends to sit outside public market coverage but squarely inside the mandate of funds built to identify pre-IPO and growth-stage opportunities.

Alternative Investment Funds focused on India's manufacturing and SME growth story, including funds like VentureX Fund India, have increasingly built exposure to this kind of thematic tailwind, treating pharma-adjacent manufacturing as one of several structural growth pockets within India's broader industrial expansion, alongside sectors benefiting from similar cost, capacity, and policy dynamics.

None of this makes the CRDMO opportunity a guaranteed outcome. India's innovation ecosystem still trails the US and Europe on the research-intensive end of drug development. Talent depth in newer modalities like biologics and gene therapy remains a genuine constraint, not just a line item to fix. Regulatory friction, while improving, still adds unpredictability that Western and even Chinese competitors don't face to the same degree. And capacity expansion requires real capital expenditure over multi-year timelines, meaning the payoff for investors isn't instant.

The upside case is real. It just isn't a straight line.

Conclusion

India's CRDMO sector is still a small fraction of a $303 billion global market, but the trajectory matters more than the current base. Cost advantages, faster project timelines, a genuine supply chain diversification tailwind, and government-backed capital are converging at the same moment newer, higher-growth drug categories are opening up. For investors thinking about India's manufacturing story beyond the obvious large-cap names, pharma CRDMO capacity, and the SME-scale companies building it, is one of the more structurally interesting corners to be watching right now.